Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.68 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.68 |
| ▸ | TDP2 | O95551 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 2/20 | 0.53 |
| ▸ | GRM5 | P41594 | 4/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.49 |
| ▸ | PIM1 | P11309 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | S100A4 | P26447 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391991 | 0.84 | PARP10 (0.68) | PARP10PARP11TDP2CA12CA9 | |
| SCHEMBL29506974 | 0.84 | PARP10 (0.68) | PARP10PARP11TDP2CA12CA9 | |
| SCHEMBL30573213 | 0.81 | PARP10 (0.59) | PARP10PARP11TDP2PARP1METAP1 | |
| SCHEMBL1002712 | 0.81 | PARP10 (1.00) | PARP10PARP11TDP2PARP1GRM5 | |
| SCHEMBL26523922 | 0.80 | GRM5 (0.51) | PARP10PARP11TDP2CA12CA9 | |
| SCHEMBL3569255 | 0.79 | PARP10 (0.45) | PARP10PARP11TDP2CA12CA9 | |
| SCHEMBL3569257 | 0.79 | PARP10 (0.45) | PARP10PARP11TDP2CA12CA9 | |
| SCHEMBL17797572 | 0.78 | PARP10 (0.81) | PARP10PARP11TDP2PARP1GRM5 | |
| SCHEMBL10286762 | 0.76 | CA12 (0.53) | PARP10PARP11CA12CA9PARP1 | |
| SCHEMBL618639 | 0.76 | CA12 (0.53) | CA12CA9PARP1GRM5CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117551083-A | Aromatic amide compound and preparation method and application thereof | 中山大学 | 2024-02-13 | — | — | CN | claimed |
| EP-4735422-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | Sanofi (FR) | 2026-05-06 | — | — | EP | disclosed |
| EP-4724441-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | Revir Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025264844-A1 | HETEROCYCLIC GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| US-20250304552-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | SEAL ROCK THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-15 | — | — | US | disclosed |
| EP-1726585-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| EP-1709022-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005073205-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | PARP10 1446/4885PARP11 977/4885TDP2 2016/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | PARP10 1446/4885PARP11 977/4885TDP2 2016/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | PARP10 3928/4885PARP11 2087/4885TDP2 3949/4885 |
| US-20250304552-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | ATF1, MAP3K1, ROCK1 | PARP10 1332/4885PARP11 476/4885TDP2 1125/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | PARP10 427/4885PARP11 563/4885TDP2 1526/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | PARP10 705/4885PARP11 319/4885TDP2 1529/4885 |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | STING1, IRF3, MAVS | PARP10 709/4885PARP11 623/4885TDP2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.